DDX5 and hepatocellular carcinoma: DDX5 sensitizes hepatocellular carcinoma (HCC) to sorafenib by inhibiting Wnt/β-catenin signaling and inducing ferroptosis, offering a promising therapeutic strategy when overexpressed in combination with multi-tyrosine kinase inhibitors (mTKIs).